AQR Capital Management LLC Reduces Holdings in Surmodics, Inc. (NASDAQ:SRDX)

AQR Capital Management LLC trimmed its position in shares of Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 53.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 20,228 shares of the company's stock after selling 23,084 shares during the quarter. AQR Capital Management LLC owned about 0.14% of Surmodics worth $850,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SRDX. SG Americas Securities LLC boosted its holdings in shares of Surmodics by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company's stock valued at $151,000 after acquiring an additional 660 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in shares of Surmodics by 13.4% during the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company's stock valued at $166,000 after acquiring an additional 673 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Surmodics by 7.5% during the 1st quarter. BNP Paribas Financial Markets now owns 6,878 shares of the company's stock valued at $202,000 after acquiring an additional 481 shares during the last quarter. Hardin Capital Partners LLC purchased a new stake in shares of Surmodics during the 2nd quarter valued at about $206,000. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in shares of Surmodics during the 1st quarter valued at about $223,000. 96.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SRDX has been the topic of several recent research reports. StockNews.com initiated coverage on shares of Surmodics in a research note on Sunday, October 6th. They issued a "hold" rating on the stock. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a research note on Monday, August 5th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $50.00.

Surmodics Stock Performance

NASDAQ SRDX traded down $0.09 on Friday, reaching $38.57. 249,521 shares of the stock were exchanged, compared to its average volume of 226,161. Surmodics, Inc. has a one year low of $25.17 and a one year high of $42.44. The firm has a market capitalization of $550.39 million, a PE ratio of -385.70 and a beta of 1.20. The company's 50-day simple moving average is $39.42 and its two-hundred day simple moving average is $37.27. The company has a current ratio of 3.98, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.04. Surmodics had a negative net margin of 1.16% and a positive return on equity of 3.88%. The company had revenue of $30.34 million for the quarter, compared to analysts' expectations of $30.32 million. Analysts expect that Surmodics, Inc. will post -0.47 EPS for the current fiscal year.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).